KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables (2016 - 2025)

Sarepta Therapeutics has reported Receivables over the past 15 years, most recently at $502.3 million for Q4 2025.

  • Quarterly results put Receivables at $502.3 million for Q4 2025, down 21.09% from a year ago — trailing twelve months through Dec 2025 was $502.3 million (down 21.09% YoY), and the annual figure for FY2025 was $502.3 million, down 21.09%.
  • Receivables for Q4 2025 was $502.3 million at Sarepta Therapeutics, down from $524.4 million in the prior quarter.
  • Over the last five years, Receivables for SRPT hit a ceiling of $714.6 million in Q1 2025 and a floor of $133.3 million in Q1 2021.
  • Median Receivables over the past 5 years was $320.1 million (2023), compared with a mean of $354.1 million.
  • Biggest five-year swings in Receivables: skyrocketed 97.39% in 2023 and later dropped 21.09% in 2025.
  • Sarepta Therapeutics' Receivables stood at $153.0 million in 2021, then surged by 42.43% to $217.9 million in 2022, then skyrocketed by 97.39% to $430.1 million in 2023, then soared by 48.0% to $636.6 million in 2024, then decreased by 21.09% to $502.3 million in 2025.
  • The last three reported values for Receivables were $502.3 million (Q4 2025), $524.4 million (Q3 2025), and $600.6 million (Q2 2025) per Business Quant data.